Abstract
Atherosclerosis is currently viewed as an inflammatory disease in which the initiation and progression of the atherosclerotic plaque towards a rupture prone, unstable plaque is driven by leukocyte recruitment mediated by various inflammatory mediators. Recently, interest in chemotactic cytokines or chemokines with regard to atherosclerosis has been growing as chemokines mediate the influx of leukocytes that is typical of atherothrombosis. The activity of the majority of chemokines is overlapping and chemokines are not only produced by the various cellular constituents of the atherosclerotic plaque but also by activated platelets. Consequently, the direct influence of individual chemokines on plaque destabilisation and rupture is widespread and rather unclear. Experimental research has already established the role of a number of chemokines in advanced atherosclerosis. Nevertheless, given the complexity and size of the chemokine family, further screening of cardiovascular disease for chemokine level and genetic polymorphisms for chemokines will be warranted as the search for viable biomarkers of plaque destabilization as well as novel therapeutic targets for specific atheroregressive therapeutic compounds is ongoing. With regard to the latter, clinical trials with specific chemokine inhibitory strategies, like chemokine receptor antagonists, are already underway in other inflammatory disorders. Summarizing, chemokine inhibition likely constitutes an important therapeutic option next to already established drugs in the management of cardiovascular disease.
Keywords: Atherosclerosis, chemokines, vulnerable plaque, cardiovascular diseases, leukocytes, platelets, therapeutics
Current Pharmaceutical Design
Title: Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Volume: 13 Issue: 10
Author(s): A. O. Kraaijeveld, S. C. A. de Jager, T. J. C. van Berkel, E. A. L. Biessen and J. W. Jukema
Affiliation:
Keywords: Atherosclerosis, chemokines, vulnerable plaque, cardiovascular diseases, leukocytes, platelets, therapeutics
Abstract: Atherosclerosis is currently viewed as an inflammatory disease in which the initiation and progression of the atherosclerotic plaque towards a rupture prone, unstable plaque is driven by leukocyte recruitment mediated by various inflammatory mediators. Recently, interest in chemotactic cytokines or chemokines with regard to atherosclerosis has been growing as chemokines mediate the influx of leukocytes that is typical of atherothrombosis. The activity of the majority of chemokines is overlapping and chemokines are not only produced by the various cellular constituents of the atherosclerotic plaque but also by activated platelets. Consequently, the direct influence of individual chemokines on plaque destabilisation and rupture is widespread and rather unclear. Experimental research has already established the role of a number of chemokines in advanced atherosclerosis. Nevertheless, given the complexity and size of the chemokine family, further screening of cardiovascular disease for chemokine level and genetic polymorphisms for chemokines will be warranted as the search for viable biomarkers of plaque destabilization as well as novel therapeutic targets for specific atheroregressive therapeutic compounds is ongoing. With regard to the latter, clinical trials with specific chemokine inhibitory strategies, like chemokine receptor antagonists, are already underway in other inflammatory disorders. Summarizing, chemokine inhibition likely constitutes an important therapeutic option next to already established drugs in the management of cardiovascular disease.
Export Options
About this article
Cite this article as:
Kraaijeveld O. A., A. de Jager C. S., C. van Berkel J. T., L. Biessen A. E. and Jukema W. J., Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?, Current Pharmaceutical Design 2007; 13 (10) . https://dx.doi.org/10.2174/138161207780487584
DOI https://dx.doi.org/10.2174/138161207780487584 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Triglyceride Level Affecting Shared Susceptibility Genes in Metabolic Syndrome and Coronary Artery Disease
Current Medicinal Chemistry Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Theoretical Possibilities for the Development of Novel Antiarrhythmic Drugs
Current Medicinal Chemistry Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Importance of Oral Health in Pregnancy: A Mini-symposium
Current Women`s Health Reviews Prevalence of Diabetes Among Immigrants in the Nordic Countries
Current Diabetes Reviews The Role of the Endothelium in the Pathogenesis of Atherosclerosis and its Therapeutic Implications
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Lipid-lowering Drug Therapy in Elderly Patients
Current Pharmaceutical Design Effect of Chronic Melatonin Administration on Several Physiological Parameters from Old Wistar Rats and Samp8 Mice
Current Aging Science Vulnerable Atherosclerotic Plaque: Clinical Implications
Current Vascular Pharmacology The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Roles of UDP-Glucuronosyltransferases in Phytochemical Metabolism of Herbal Medicines and the Associated Herb-Drug Interactions
Current Drug Metabolism Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging Drugs Targeting the Canonical NF-κB Pathway to Treat Viral and Autoimmune Myocarditis
Current Pharmaceutical Design Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Congenital Heart Disease: The Crossroads of Genetics, Epigenetics and Environment
Current Genomics Dasabuvir: A Non-Nucleoside Inhibitor of NS5B for the Treatment of Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Nanotechnology Based Diagnostic and Therapeutic Strategies for Neuroscience with Special Emphasis on Ischemic Stroke
Current Medicinal Chemistry